

## **COVID-19 Vaccine Screening Form**

Version 4.0 – March 25, 2022

| Last Name  |               | Identification number (e.g., health card) |
|--|---------------|---|
| First Name   |               |   |
| Date of Birth (month, day, year)   |               | Name of your Primary Care Provider        |
| / /  |               | (Family Physician or Nurse Practitioner)  |
| Gender: 🗆 Female 🗆 Male 🗆 Prefer not to  |               |   |
| answer 🗆 Other:  |               |   |
| Phone Number   | Email Address |   |
| Have you previously received one or more doses of a COVID-19 vaccine? If yes, please |               |   |
| complete the information below for all doses of vaccine received.                    |               |   |
| Number of doses received to date:  |               |   |
| Date of last dose received:// (month, day, year)                                     |               |   |

## Please answer all questions below.

Screening questions determine if additional precautions or information is required. Note that answering 'yes' does not necessarily mean an individual cannot receive the vaccine

| Have you been sick in the past few days? Do you<br>have symptoms of COVID-19 today (e.g., loss of<br>taste or smell, cough, fever)? If applicable, have you<br>completed your period of isolation?<br>No | If yes, please provide details<br>Immunization should be deferred in<br>individuals with symptoms of COVID-<br>19 to prevent the spread of infection to<br>others. Individuals should consult with<br>a health care provider or call<br>Telehealth to discuss their symptoms.<br>A health care provider can advise on a<br>suitable time to receive the COVID-19<br>vaccine. |
|--|--|
|  | Individuals 12 years of age and older,<br>infected with COVID-19 after their<br>primary series are recommended to<br>receive their booster dose 3 months<br>after symptom onset or positive test (if<br>asymptomatic). With informed<br>consent, individuals may receive a<br>booster dose once they are<br>asymptomatic and have completed<br>their isolation.              |
| Have you recently had any new/unexplained<br>shortness of breath or chest pain?<br>□ No □ Yes  | If yes, please provide details<br>Immunization should be deferred, and<br>individuals should consult with a<br>health care provider prior to<br>vaccination and/or if symptoms are<br>severe, individuals should be directed<br>to the emergency department or<br>instructed to call 911.  |

| Have you had a serious allergic reaction<br>(anaphylaxis) within 4 hours to the COVID-19<br>vaccine before, needing medical care?<br>□ No □ Yes  | If yes, please provide details<br>It may be possible for individuals with<br>a previous allergic reaction to a<br>COVID-19 vaccine to receive the same<br>type of vaccine again. Individuals<br>should consult with a health care<br>provider prior to receiving the COVID-<br>19 vaccine.   |
|--|--|
| Have you been formally diagnosed with any serious<br>allergies (anaphylaxis) to polyethylene glycol (PEG),<br>tromethamine (Tris or trometamol), or polysorbate<br>80?<br>□ No □ Yes   | If yes, please provide details<br>Individuals allergic to polyethylene<br>glycol, tromethamine, or polysorbate<br>80 should consult with a health care<br>provider prior to receiving the COVID-<br>19 vaccine.  |
| Have you ever had myocarditis (inflammation of the heart) or pericarditis (inflammation of the lining of the heart) before?  No Yes If yes, which of the following apply? Following vaccination of a COVID-19 vaccine Unrelated to vaccination of a COVID-19 vaccine | If following vaccination of a COVID-19<br>vaccine:<br>As a precautionary measure, the<br>National Advisory Committee on<br>Immunization (NACI) has<br>recommended individuals who have<br>experienced myocarditis or pericarditis<br>following vaccination with an mRNA<br>COVID-19 vaccine defer their<br>subsequent dose in the vaccination<br>series until more information is<br>available.<br>If unrelated to receiving a COVID-19<br>vaccine:<br>Individuals with a history of<br>myocarditis unrelated to mRNA<br>COVID-19 vaccination should consult a<br>health care provider for individual<br>considerations and recommendations<br>prior to receiving the COVID-19<br>vaccine. |

| immune system (e.g., high dose steroids, chemotherapy)?   | Individuals who are<br>immunocompromised from disease or<br>treatment may have a reduced  |  |
|---|---|--|
|   | immune response to the COVID-19   |  |
| If yes, are you receiving stem cell therapy, chimeric-<br>antigen receptor (CAR) T-cell therapy,<br>chemotherapy, immune checkpoint inhibitors,<br>monoclonal antibodies, or other targeted agents?<br>□ No □ Yes | vaccine series. In addition to at least<br>two doses of vaccine, continued<br>adherence to public health measures<br>after vaccination (such as masking,<br>physical distancing, and hand hygiene)<br>is encouraged. A health care provider<br>can advise on a time to receive the<br>COVID-19 vaccine to ensure an optimal<br>immune response. |  |
| Do you have a bleeding disorder or are taking blood thinners?   | If yes, please provide details  |  |
|   | If "yes", a health care worker may hold<br>the site where the needle is given for<br>longer to minimize the risk of bleeding<br>and bruising.   |  |
| Have you ever felt faint or fainted after receiving a   | If yes, please provide details  |  |
| vaccine or medical procedure?   | If "yes", a health care provider may instruct an individual to lie down to be vaccinated to prevent fainting.   |  |
| Only answer the following two questions if receiving the Pfizer-BioNTech pediatric COVID-<br>19 mRNA vaccine  |   |  |
| Do you have a previous history of multisystem   | If yes, please provide details  |  |
| inflammatory syndrome?<br>□ No □ Yes  | For children 5-11 years old with a<br>previous history of MIS-C unrelated to<br>any previous COVID-19 vaccination,<br>vaccination should be postponed until<br>clinical recovery has been achieved or<br>until it has been ≥ 90 days since<br>diagnosis, whichever is longer.   |  |

| Have you received another vaccine (not a COVID-19<br>vaccine) in the past 14 days?  | If yes, please provide details<br>Unlike adolescent and adult<br>populations, COVID-19 vaccines<br>should not be given concomitantly for<br>children 5-11 years old with other<br>vaccines (live or inactivated).<br>Vaccination should be postponed at<br>least 14 days before or after to prevent<br>erroneous attribution of an adverse<br>event following immunization from<br>one vaccine to another. |  |  |
|---|--|--|--|
| Only answer the following five questions if receiving the AstraZeneca Vaxzevria or Janssen<br>(Johnson & Johnson) COVID-19 viral vector vaccine:                |  |  |  |
| Do you have a history of blood clots (thrombosis)<br>with low platelets (thrombocytopenia) after a<br>COVID-19 vaccine?<br>I No I Yes                           | If yes, please provide details<br>Individuals who have had blood clots<br>with low platelet after a previous viral<br>vector vaccine (AstraZeneca or<br>Janssen) should not receive the<br>AstraZeneca or Janssen COVID-19<br>vaccine.   |  |  |
| Have you experienced a previous episode of<br>capillary leak syndrome (CLS) (symptoms include<br>low blood pressure and acute swelling of limbs)?<br>□ No □ Yes | If yes, please provide details<br>Individuals who have had a previous<br>episode of capillary leak syndrome are<br>advised not to receive the<br>AstraZeneca or Janssen COVID-19<br>vaccine. Individuals should consult<br>with a health care provider before<br>receiving the AstraZeneca or Janssen<br>COVID-19 vaccine.   |  |  |

| Do you have a history of major blood clots with low<br>platelets (a part of the blood that helps with<br>clotting) or low platelets after receiving heparin<br>therapy?<br>□ No □ Yes | If yes, please provide details<br>Rarely, low platelets can occur after<br>the AstraZeneca and Janssen vaccine.<br>Individuals with a history of low<br>platelets should consider receiving an<br>mRNA vaccine. Individuals with a<br>history of low platelets receiving the<br>AstraZeneca or Janssen vaccine<br>should watch for easy bruising or<br>excess bleeding that is unexplained. A<br>health care provider may monitor an<br>individual's blood platelet count after<br>receiving the AstraZeneca or Janssen<br>vaccine. Individuals may choose to<br>discuss their risks with a health care<br>provider. |
|---|--|
| Are you or could you be pregnant?   | If yes, please provide details<br>Evidence is now available from real<br>world use of mRNA vaccines, which<br>has not indicated any safety concerns<br>for pregnant and breastfeeding<br>populations. There is more evidence<br>available regarding the safety of<br>mRNA vaccines for pregnant and<br>breastfeeding populations, so an<br>mRNA vaccine is preferred by the<br>National Advisory Committee on<br>Immunization (NACI). Individuals<br>should consult with a health care<br>provider if they wish to have<br>AstraZeneca Vaxzevria or Janssen<br>(Johnson & Johnson) COVID-19<br>vaccine.              |